☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or othe ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q2 2019 Earnings Conference Call August 6, 2019 8:00 AM ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President & CEO Kim Brazzell - CMO Todd Bazemore - COO Conference Call Participants Biren Amin - Jefferies Esther Rajavelu - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning, and welcome to Kala Pharmaceuticals Second Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management's ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Large accelerated filer ☐ Acceler ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Mary Reumuth – Chief Financial Officer Mark Iwicki – Chairman, President and Chief Executive Officer Todd Bazemore – Chief Operating Officer Kim Brazzell – Chief Medical Officer Hongming Chen – Chief Scientific Officer Conference Call Participants Shveta Vilas – Wedbush Esther Rajavelu – Oppenheimer Yi Chen – H.C. Wainwright Operator Good morning, and welcome to Kala Pharmaceuticals First Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or other ju ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer Conference Call Participants David Maris - Wells Fargo Liana Moussatos - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day, and welcome to Kala Pharmaceuticals Fourth Quarter 2018 Earnings Conference Call. At this time, al ...